An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

Patients value communication skills from cancer surgeons across six key areas, according to research

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Lesser-known lobular breast cancer on the rise in U.S. women

Mindfulness-based interventions are advised by cancer organizations to treat patients' anxiety and depression.

Recommended Articles For You

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment 

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV

2.

According to JAMA, statin use may increase cancer-related survival in breast cancer patients.

3.

How a California Oncologist Making $850k Spends Money

4.

iPSC-based vaccines: A new hope for preventing and treating colorectal cancer

5.

Alkem introduces cetuximab under the trade name Cetuxa in India.

1.

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed

2.

Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy

3.

Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer

4.

Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025

5.

Priming Agents: A Novel Approach to Enhancing Cell-Free DNA Detection in Liquid Biopsies

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

2.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

4.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot